GlassScriptPhysician profile
Bani A Sarma
NPI 1023018132
$169.70
in general payments reported to CMS, 2019-2025
9 companies · $28.50 in 2025
The $28.50 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.07 · 2020: $44.13 · 2025: $28.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $28.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $28.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $43.21 | 2019-2020 | |
| Astellas Pharma US INC | $28.50 | 2025 | Veozah |
| Exeltis, USA INC. | $28.02 | 2019-2020 | |
| Pfizer INC. | $15.00 | 2019 | |
| Merck Sharp & Dohme LLC | $14.64 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.26 | 2019 | |
| Celularity INC. | $14.00 | 2019 | |
| Abbvie INC. | $12.07 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bani Sarma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.